Crazy Flux
  • Business
  • World
  • Stocks
  • Investing
  • Business
  • World
  • Stocks
  • Investing

Crazy Flux

Business

Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

by admin April 30, 2025
April 30, 2025
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. 

Bourla’s remarks on the company’s first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations that would push the company to increase investments in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost domestic manufacturing.

“If I know that there will not be tariffs … then there are tremendous investments that can happen in this country, both in R&D and manufacturing,” Bourla said on the call, adding that the company is also hoping for “certainty.”

“In periods of uncertainty, everybody is controlling their cost as we are doing, and then is very frugal with their investment, as we are doing, so that we are prepared for remit. So that’s what I want to see,” Bourla said.

Bourla noted the tax environment, which had previously pushed manufacturing abroad, has “significantly changed now” with the establishment of a global minimum tax of around 15%. He said that shift hasn’t necessarily made the U.S. more attractive, saying “it’s not as good” to invest here without additional incentives or clarity around tariffs.

“Now [Trump] I’m sure — and I know because I talked to him — that he would like to see even a reduction in the current tax regime particularly for locally produced goods,” Bourla said, adding a further decrease would be would be a strong incentive for manufacturing in the U.S.

Unlike other companies grappling with evolving trade policy, Pfizer did not revise its full-year outlook on Tuesday. However, the company noted in its earnings release that the guidance “does not currently include any potential impact related to future tariffs and trade policy changes, which we are unable to predict at this time.”

But on the earnings call on Tuesday, Pfizer executives said the guidance does reflect $150 million in costs from Trump’s existing tariffs.

“Included in our guidance that we didn’t really speak about is there are some tariffs in place today,” Pfizer CFO Dave Denton said on the call.

“We are contemplating that within our guidance range and we continue to again trend to the top end of our guidance range even with those costs to be incurred this year,” he said.

This post appeared first on NBC NEWS

previous post
Trial of gang accused of robbing Kim Kardashian at gunpoint opens in Paris
next post
IBM pledges $150 billion to boost U.S. tech growth, computer manufacturing

Related Posts

Applebee’s owner Dine Brands to lean on value,...

March 8, 2025

Byron Allen puts broadcast TV stations up for...

June 4, 2025

Boeing would avoid guilty plea, prosecution over 737...

May 18, 2025

USPS resumes shipments from China in abrupt about-face

February 6, 2025

Walmart is using its own fintech firm to...

June 11, 2025

How America’s chief consumer-protection agency came into the...

February 14, 2025

Paramount ends DEI policies, cites Trump executive order

February 28, 2025

Amazon AI scammers duped investors out of millions...

March 20, 2025

’60 Minutes’ producer leaves show, citing a loss...

April 24, 2025

Netflix stock is trading at all-time high levels...

May 4, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • North Korea to send as many as 30,000 troops to bolster Russia’s forces, Ukrainian officials say

      July 3, 2025
    • Catherine, Princess of Wales makes first public appearance after dropping out of Royal Ascot

      July 3, 2025
    • Iran’s president approves law suspending cooperation with UN nuclear watchdog

      July 3, 2025
    • Could a ceasefire finally be struck in Gaza? Here’s what to know

      July 3, 2025
    • US teen influencer detained in Antarctica while attempting solo flight to 7 continents

      July 3, 2025
    • UK lawmakers vote to ban pro-Palestinian activist group under anti-terror law despite condemnation

      July 3, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: crazyflux.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 crazyflux.com | All Rights Reserved